Glen Eagle Advisors, LLC Cidara Therapeutics, Inc. Transaction History

Glen Eagle Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.51 - $14.37 $51 - $1,437	-100 Closed	0 $0
Q3 2018 Aug 13, 2024	SELL	$3.7 - $5.25 $370 - $525	-100 Closed	0 $0
Q1 2018 Aug 14, 2024	BUY	$4.0 - $8.15 $400 - $815	100 New	100 $400,000
Q3 2017 Aug 13, 2024	BUY	$5.75 - $8.1 $575 - $810	100 New	100 $810,000
Q1 2017 Aug 12, 2024	SELL	N/A	-300 Reduced 75.0%	100 $780,000
Q4 2016 Aug 12, 2024	BUY	N/A	400	400 $4.16 Million

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $813M
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.